GKOS - Glaukos Corporation

NYSE - NYSE Delayed Price. Currency in USD
74.35
-0.15 (-0.20%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close74.50
Open74.50
Bid74.40 x 1200
Ask74.48 x 1200
Day's Range73.50 - 75.14
52 Week Range36.89 - 83.14
Volume364,518
Avg. Volume381,681
Market Cap2.669B
Beta (3Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est75.00
Trade prices are not sourced from all markets
  • This Is What Hedge Funds Think About Glaukos Corporation (GKOS)
    Insider Monkey4 days ago

    This Is What Hedge Funds Think About Glaukos Corporation (GKOS)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]

  • Benzinga7 days ago

    The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 19) Abbott Laboratories (NYSE: ABT ) CareDx Inc (NASDAQ: ...

  • Business Wire8 days ago

    Glaukos Corporation Enters into Definitive Agreement to Acquire DOSE Medical Corporation

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has entered into a definitive Agreement and Plan of Merger to acquire DOSE Medical Corporation (DOSE Medical) for $2.5 million in cash, plus performance-based consideration upon achievement of certain regulatory approvals and commercial milestones. Upon the consummation of the acquisition, DOSE Medical will become a wholly owned subsidiary of Glaukos.

  • Markit16 days ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Glaukos Corp NYSE:GKOSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for GKOS with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 3. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding GKOS are favorable, with net inflows of $1.22 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Has Glaukos Corporation (NYSE:GKOS) Got Enough Cash?
    Simply Wall St.20 days ago

    Has Glaukos Corporation (NYSE:GKOS) Got Enough Cash?

    Mid-caps stocks, like Glaukos Corporation (NYSE:GKOS) with a market capitalization of US$2.5b, aren’t the focus of...

  • Glaukos (GKOS) Down 2.5% Since Last Earnings Report: Can It Rebound?
    Zacks20 days ago

    Glaukos (GKOS) Down 2.5% Since Last Earnings Report: Can It Rebound?

    Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire23 days ago

    International Study Confirms Significant, Sustained IOP and Medication Reduction Following Standalone Implantation of Glaukos’ iStent inject® in Glaucoma Patients with Substantial Disease Burden

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an independent, international study published in Advances in Therapy showed standalone implantation of the iStent inject® Trabecular Micro-Bypass System in eyes with substantial glaucoma disease burden achieved a 42% reduction in mean intraocular pressure (IOP) to 14.6 mmHg and an 82% reduction in mean medications to 0.55 at three years postoperative.

  • Glaukos (GKOS) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Glaukos (GKOS) Q1 2019 Earnings Call Transcript

    GKOS earnings call for the period ending March 31, 2019.

  • Does This Valuation Of Glaukos Corporation (NYSE:GKOS) Imply Investors Are Overpaying?
    Simply Wall St.2 months ago

    Does This Valuation Of Glaukos Corporation (NYSE:GKOS) Imply Investors Are Overpaying?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of GKOS earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Glaukos Corp Earnings Call

  • Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

    Glaukos (GKOS) delivered earnings and revenue surprises of 66.67% and 7.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Glaukos: 1Q Earnings Snapshot

    On a per-share basis, the San Clemente, California-based company said it had a loss of 4 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wire2 months ago

    Glaukos Corporation Announces First Quarter 2019 Financial Results

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the first quarter ended March 31, 2019.

  • ACCESSWIRE2 months ago

    Glaukos Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Glaukos Corp. (NYSE: GKOS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time. To ...

  • Business Wire2 months ago

    Multiple Surgeons to Present Data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that numerous surgeons will present clinical trial and real-world data regarding it products at the American Society of Cataract and Refractory ...

  • Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for
    Zacks2 months ago

    Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for

    Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Did Hedge Funds Drop The Ball On Glaukos Corporation (GKOS)?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On Glaukos Corporation (GKOS)?

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Business Wire2 months ago

    Glaukos Announces Participation in Bank of America Merrill Lynch 2019 Health Care Conference

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019, at 3:40 p.m. PDT in Las Vegas, Nevada.

  • Business Wire2 months ago

    Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States

    Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) and Glaukos Corporation (“Glaukos” NYSE: GKOS), announced today that Santen’s U.S. subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt (development code: DE-128) solely in the U.S. market. The MicroShunt is a novel, minimally-invasive, ab-externo surgical device being developed for primary open-angle glaucoma (POAG). Glaucoma is a leading cause of irreversible blindness, affecting several million people in the United States.

  • Business Wire2 months ago

    Glaukos Corporation to Release First Quarter 2019 Financial Results after Market Close on May 8

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release first quarter 2019 financial results after the market close on Wednesday, May 8, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 8, 2019.

  • Business Wire2 months ago

    Prospective, Randomized Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents® vs. Topical Prostaglandin in Newly Diagnosed Glaucoma Patients

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent® Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35.3% reduction in mean intraocular pressure (IOP) to 16.5 mmHg after five years of follow-up.

  • Is Glaukos Corporation (NYSE:GKOS) A Volatile Stock?
    Simply Wall St.2 months ago

    Is Glaukos Corporation (NYSE:GKOS) A Volatile Stock?

    If you own shares in Glaukos Corporation (NYSE:GKOS) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volat...